Astrana Health, Inc. reported a strong start to 2025 with total revenue increasing by 53% to $620.4 million. However, net income attributable to Astrana decreased to $6.7 million from $14.8 million in the prior year, and diluted EPS fell to $0.14 from $0.31. Adjusted EBITDA also saw a decrease to $36.4 million from $42.2 million.
Total revenue increased by 53% to $620.4 million in Q1 2025, up from $404.4 million in Q1 2024.
Care Partners revenue grew by 57% to $601.0 million, compared to $382.3 million in the same period last year.
Net income attributable to Astrana decreased to $6.7 million in Q1 2025 from $14.8 million in Q1 2024.
Diluted earnings per share (EPS) for Q1 2025 were $0.14, down from $0.31 in Q1 2024.
Astrana Health is providing guidance for total revenue and Adjusted EBITDA for the quarter ending June 30, 2025, and reiterating guidance for the full year ending December 31, 2025, based on existing business conditions and assumptions. The full-year guidance includes approximately $15 million in expected costs for strategic investments in automation and AI, as well as integration costs for planned acquisitions, but excludes contributions from unclosed acquisitions.
Analyze how earnings announcements historically affect stock price performance